Zobrazeno 1 - 10
of 323
pro vyhledávání: '"Millie D. Long"'
Autor:
Margie Boccieri, Riley Craig, Xian Zhang, Ann M. Firestine, Millie D. Long, Michael D. Kappelman
Publikováno v:
Journal of Clinical and Translational Science, Vol 8 (2024)
Abstract Introduction: Disparities in the recruitment of minority populations in research are well-documented. However, the degree of participation and retention of minorities following enrollment is less known, particularly in decentralized studies
Externí odkaz:
https://doaj.org/article/6fec53b0b6c0470fafb66db319c341b0
Autor:
David T. Rubin, Leonardo Salese, Mitchell Cohen, Paulo G. Kotze, John C. Woolcott, Chinyu Su, Rajiv Mundayat, Jerome Paulissen, Joana Torres, Millie D. Long
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Objective: To assess colectomy incidence rates (IRs) and baseline characteristics for the presence of identified colectomy risk fac
Externí odkaz:
https://doaj.org/article/4f14d6481d204724942026dae5b142a5
Autor:
Erica J. Brenner, Li Lin, Kirsten M. Bahnson, Millie D. Long, Wenli Chen, Michael D. Kappelman, Bryce B. Reeve
Publikováno v:
Journal of Clinical and Translational Science, Vol 7 (2023)
Abstract Introduction: Computerized-adaptive testing (CAT) may increase reliability or reduce respondent burden for assessing patient-reported outcomes compared with static short forms (SFs). We compared CAT versus SF administration of the Patient-R
Externí odkaz:
https://doaj.org/article/5a6c26f5cf944dd18d65e3f145e5fbf2
Autor:
Benjamin Click, Edward L. Barnes, Benjamin L. Cohen, Bruce E. Sands, John S. Hanson, David T. Rubin, Marla C. Dubinsky, Miguel Regueiro, Derek Gazis, Julie M. Crawford, Millie D. Long
Publikováno v:
BMC Gastroenterology, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Inflammatory bowel disease (IBD) treatment paradigms recommend objective disease activity assessment and reactive therapeutic drug monitoring (TDM) prior to changes in biologic therapy. We aimed to describe objective marker and TD
Externí odkaz:
https://doaj.org/article/c94a6d498f654c49b59bc62a2e6ffb57
Autor:
Matt Kanke, Meaghan M. Kennedy Ng, Sean Connelly, Manvendra Singh, Matthew Schaner, Michael T. Shanahan, Elizabeth A. Wolber, Caroline Beasley, Grace Lian, Animesh Jain, Millie D. Long, Edward L. Barnes, Hans H. Herfarth, Kim L. Isaacs, Jonathon J. Hansen, Muneera Kapadia, Jose Gaston Guillem, Cedric Feschotte, Terrence S. Furey, Shehzad Z. Sheikh, Praveen Sethupathy
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 13, Iss 6, Pp 1717-1740 (2022)
Background & Aims: The intestinal barrier comprises a monolayer of specialized intestinal epithelial cells (IECs) that are critical in maintaining mucosal homeostasis. Dysfunction within various IEC fractions can alter intestinal permeability in a ge
Externí odkaz:
https://doaj.org/article/f26eceddd75d46159db62af17e2aa45c
Autor:
Edward L. Barnes, Joshua Hudson, Scott Esckilsen, Bharati Kochar, Michael D. Kappelman, Millie D. Long, Mark Koruda, Robert S. Sandler, Hans H. Herfarth
Publikováno v:
Inflammatory Intestinal Diseases, Pp 1-8 (2021)
Background: The most common complication following ileal pouch-anal anastomosis (IPAA) in patients with ulcerative colitis (UC) is pouchitis. Our study aimed to investigate the relationship between histopathologic findings of ileitis, granuloma, or t
Externí odkaz:
https://doaj.org/article/dfcbf5036e31493982e6e42d6e4f7583
Autor:
Takahiko Toyonaga, Kenza C. Araba, Meaghan M. Kennedy, Benjamin P. Keith, Elisabeth A. Wolber, Caroline Beasley, Erin C. Steinbach, Matthew R. Schaner, Animesh Jain, Millie D. Long, Edward L. Barnes, Hans H. Herfarth, Kim L. Isaacs, Jonathan J. Hansen, Muneera R. Kapadia, José Gaston Guillem, Ajay S. Gulati, Praveen Sethupathy, Terrence S. Furey, Camille Ehre, Shehzad Z. Sheikh
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract The host receptor for SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2), is highly expressed in small intestine. Our aim was to study colonic ACE2 expression in Crohn's disease (CD) and non-inflammatory bowel disease (non-IBD) controls. We
Externí odkaz:
https://doaj.org/article/46dc769554ff4a93a33f60385762e0c7
Publikováno v:
Inflammatory Intestinal Diseases (2021)
Background Individuals with inflammatory bowel disease (IBD) are up to twice as likely to suffer from anxiety and/or depression. Collaborative care management (CoCM) is an evidenced-based approach to treating behavioral health disorders that has prov
Externí odkaz:
https://doaj.org/article/6c489ec5aa6d4bc69febc1355949fcd6
Autor:
Takahiko Toyonaga, Erin C. Steinbach, Benjamin P. Keith, Jasmine B. Barrow, Matthew R. Schaner, Elisabeth A. Wolber, Caroline Beasley, Jennifer Huling, Yuli Wang, Nancy L. Allbritton, Nicole Chaumont, Timothy S. Sadiq, Mark J. Koruda, Animesh Jain, Millie D. Long, Edward L. Barnes, Hans H. Herfarth, Kim L. Isaacs, Jonathan J. Hansen, Michael T. Shanahan, Reza Rahbar, Terrence S. Furey, Praveen Sethupathy, Shehzad Z. Sheikh
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 10, Iss 4, Pp 779-796 (2020)
Background & Aims: Intestinal epithelial cell (IEC) barrier dysfunction is critical to the development of Crohn’s disease (CD). However, the mechanism is understudied. We recently reported increased microRNA-31-5p (miR-31-5p) expression in colonic
Externí odkaz:
https://doaj.org/article/36b046e473024c52aed5f45964b4cb72
Autor:
Michael D, Kappelman, Sruthi, Adimadhyam, Laura, Hou, Audrey E, Wolfe, Samantha, Smith, Andrew L, Simon, Érick, Moyneur, Juliane S, Reynolds, Sengwee, Toh, Angela, Dobes, Lauren E, Parlett, Kevin, Haynes, Mano, Selvan, Qianli, Ma, Vinit, Nair, Jessica, Burris, Jennifer E, Dorand, Ghadeer K, Dawwas, James D, Lewis, Millie D, Long
Publikováno v:
American Journal of Gastroenterology. 118:674-684
Many patients with Crohn's disease (CD) lose response or become intolerant to antitumor necrosis factor (TNF) therapy and subsequently switch out of class. We compared the effectiveness and safety of ustekinumab to vedolizumab in a large, geographica